Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset

[1]  J. Shih,et al.  Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY , 2020, Cancer science.

[2]  J. Cui,et al.  Non-small cell lung cancer patients with ex19del or exon 21 L858R mutation: distinct mechanisms, different efficacies to treatments , 2020, Journal of Cancer Research and Clinical Oncology.

[3]  Joe Y. Chang,et al.  NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  J. Shih,et al.  Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[5]  Zhen Yang,et al.  Update on liquid biopsy in clinical management of non-small cell lung cancer , 2019, OncoTargets and therapy.

[6]  T. Yamanaka,et al.  The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV , 2019, International Journal of Clinical Oncology.

[7]  A. Gemma,et al.  Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. , 2019, The Lancet. Oncology.

[8]  T. Mitsudomi,et al.  Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. , 2019, Annals of Oncology.

[9]  T. Mitsudomi,et al.  Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  S. Vowler,et al.  Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset , 2018, Japanese journal of clinical oncology.

[11]  P. V. Van Schil,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  J. Shih,et al.  Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer , 2018, Molecular Cancer.

[13]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[14]  D. Rimm,et al.  Worldwide Frequency of Commonly Detected EGFR Mutations. , 2017, Archives of pathology & laboratory medicine.

[15]  ping wang,et al.  Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer , 2017, Oncotarget.

[16]  M. Ahn,et al.  Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.

[17]  K. Wang,et al.  The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis , 2016, Oncotarget.

[18]  J. Yokota,et al.  Gene aberrations for precision medicine against lung adenocarcinoma , 2016, Cancer science.

[19]  Jing-hao Liu,et al.  Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients. , 2016, Cancer letters.

[20]  K. Nishio,et al.  Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples , 2015, Oncotarget.

[21]  Fang Wang,et al.  Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis , 2015, European Journal of Clinical Pharmacology.

[22]  Koichi Goto,et al.  Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. , 2014, The Lancet. Oncology.

[23]  P. Jänne,et al.  Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance , 2009, Clinical Cancer Research.

[24]  L. Shewchuk,et al.  Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib. , 2008, Cancer research.

[25]  L. Byers,et al.  Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer. , 2007, Clinical lung cancer.

[26]  K. Yoneda,et al.  Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma. , 2006, Clinical lung cancer.

[27]  Stuart Thomson,et al.  Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. , 2006, Cancer research.

[28]  D. Hicklin,et al.  Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. , 2001, Cancer research.